In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers

[1]  O. Nanni,et al.  Cell kinetics and hormonal features in relation to pathological stage in breast cancer , 1991, Breast Cancer Research and Treatment.

[2]  D. Amadori,et al.  An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activityin vitro: Experience on 136 primary cancers and on 116 recurrences , 2005, Breast Cancer Research and Treatment.

[3]  T. Chou,et al.  Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-Cell Viability Assay , 1993, Breast Cancer Research and Treatment.

[4]  L. Kèlland,et al.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[5]  D. Kerr,et al.  Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. , 1993, Cancer research.

[6]  N. Zaffaroni,et al.  In vitro cytotoxic activity of taxol' and taxotere on primary cultures and established cell lines of human ovarian cancer , 1993, Stem cells.

[7]  C. Fellbaum,et al.  Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. , 1993, European journal of cancer.

[8]  D. Moore,et al.  Phase I trial of Taxotere: five-day schedule. , 1992, Journal of the National Cancer Institute.

[9]  R. Weiss.  The anthracyclines: will we ever find a better doxorubicin? , 1992, Seminars in oncology.

[10]  S. Arbuck,et al.  Taxol: the first of the taxanes, an important new class of antitumor agents. , 1992, Seminars in oncology.

[11]  F. Landoni,et al.  Potentials of cell kinetics in the management of patients with ovarian cancers. , 1992, European journal of cancer.

[12]  G. Hortobagyi,et al.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[13]  M. Bissery,et al.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. , 1991, Cancer research.

[14]  D. Guénard,et al.  Relationships between the structure of taxol analogues and their antimitotic activity. , 1991, Journal of medicinal chemistry.

[15]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[16]  D. Amadori,et al.  Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. , 1990, Cancer research.

[17]  D. Guénard,et al.  Application of the Vicinal Oxyamination Reaction with Asymmetric Induction to the Hemisynthesis of Taxol and Analogues. , 1989 .

[18]  A. Greene,et al.  Highly efficient, practical approach to natural taxol , 1988 .

[19]  L. Grochow,et al.  Phase I trial of taxol in patients with advanced cancer. , 1987, Cancer treatment reports.

[20]  H. Smith,et al.  Response to doxorubicin of cultured normal and cancerous human mammary epithelial cells. , 1985, Journal of the National Cancer Institute.

[21]  R. Ceriani,et al.  Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. , 1981, Cancer research.

[22]  D. Alberts,et al.  Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. , 1980, Progress in clinical and biological research.

[23]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[24]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.